This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ENO1 / Alpha-enolase · IHC design guide
Design Immunohistochemistry for ENO1
Plan ENO1 paraffin IHC using bronchial basal cells as a positive reference (HPA tissue IHC). The catalog antibody's IHC dilution is 0.5–1 μg/mL (datasheet A01250-1); assess cytoplasmic and nuclear staining (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ENO1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and nuclear staining (HPA tissue IHC) | |
| Staining pattern | Widespread cytoplasmic and nuclear staining (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A01250-1) | |
| Positive control | Bronchus+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific). Selected-image fixative and duration unreported (datasheet A01250-1); verify before use. | |
| Caveat | Splice or transcript discrepancies may complicate interpretation (HPA tissue IHC) | |
| Regulation | Alpha/alpha occurs in most adult tissues (UniProt) | |
| Isoform / epitope | 2 isoforms: alpha-enolase and MBP-1; check epitope coverage (UniProt) |
Section 1
Recommended ENO1 IHC & IF Protocols
The catalog antibody uses EDTA pH 8.0 heat retrieval (datasheet A01250-1). Four published ENO1 IHC protocols provide additional starting conditions (PMC12571633; PMC10931177; PMC7893569; PMC3233504).
| Sample | Paraffin-embedded human liver cancer tissue; fixative not specified (datasheet A01250-1) |
| Fixation | Image fixative and duration unreported (datasheet A01250-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A01250-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A01250-1) |
| Primary antibody | Rabbit anti-ENO1, 0.5-1μg/ml (datasheet A01250-1) |
| Primary incubation | Overnight at 4 °C (datasheet A01250-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A01250-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ENO1-positive staining in basal cells of bronchus (HPA tissue IHC: High). HPA tissue profile: Ubiquitous cytoplasmic and nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A01250-1). Use the stated retrieval when reproducing a published protocol (PMC12571633; PMC3233504).
Section 2
What Is the Expected ENO1 Staining Pattern?
In paraffin IHC, expect ENO1 in cytoplasm and sometimes nuclei across many tissues, with strong staining reported in bronchial basal cells, fallopian tube non-ciliated cells, and lung alveolar type I cells (HPA tissue IHC: ubiquitous cytoplasmic and nuclear expression; High in those cells). ENO1 can also reach the cell membrane despite having no transmembrane segment (UniProt P06733: subcellular location and topology). HPA rates its tissue pattern Supported, with medium RNA–staining consistency and a splice or transcript discrepancy (HPA tissue IHC: reliability).
| Bronchial basal cells show strong cytoplasmic chromogen, with or without nuclear staining. | This fits a reported high-staining cell population and the broad tissue pattern (HPA tissue IHC: High in bronchial basal cells; ubiquitous cytoplasmic and nuclear expression). Judge compartment and cell identity together; intensity alone cannot establish specificity, especially where HPA reports only medium consistency between staining and RNA (HPA tissue IHC: reliability). |
| The strongest deposit appears exclusively in an unrelated compartment, while cytoplasm is clear. | Recheck the result against the expected cytoplasmic and nuclear tissue pattern (HPA tissue IHC: profile). Membrane-associated signal can be plausible because ENO1 may translocate there, so membrane staining alone is not an artifact (UniProt P06733: subcellular location). An isolated incompatible pattern warrants review of morphology, controls, and detection background (general IHC practice). |
| A cell population stains strongly where the chosen tissue reference predicts only low staining. | Treat this as a specificity question, not an automatic negative result: HPA lists cardiomyocytes, smooth muscle cells, skeletal myocytes, and soft-tissue fibroblasts as Low, and lists no negative population (HPA tissue IHC: low and negative lists). If staining ignores cell boundaries or persists in a no-primary control, assess nonspecific antibody binding or endogenous detection activity (general IHC practice). |
| Pale chromogen covers much of the section, including spaces between cells. | That distribution cannot be scored confidently as intracellular ENO1. Use cell outlines and a matched no-primary control to distinguish tissue signal from residual detection background (general IHC practice). Genuine ENO1 tissue staining is described as cytoplasmic and nuclear; a broad extracellular haze does not reproduce that profile (HPA tissue IHC: profile). |
| A known high-staining cell population has no convincing signal. | Check that the reference cells are present before calling the run negative: bronchial basal cells, fallopian tube non-ciliated cells, and lung alveolar type I cells are reported High (HPA tissue IHC: positive list). Then check the IHC-validated antibody, detection reagents, and a concurrent positive control; review retrieval as a general paraffin-IHC optimization step, without assuming ENO1-specific fixation sensitivity (general IHC practice). |
💡Expected ENO1 appearanceCall the result positive when cell-bound cytoplasmic staining, sometimes with nuclear staining, is convincing in an HPA High population; diffuse extracellular color or signal surviving a no-primary control suggests background (HPA tissue IHC: profile and High populations; general IHC practice).
| Tissue and cell identity | ENO1 is broadly expressed, but reported levels differ by cell population: bronchial basal cells are High, adipocytes in adipose tissue are Medium, and cardiomyocytes are Low (HPA tissue IHC: positive and low lists). Choose a reference by its named cell population rather than treating every cell in a tissue as equally positive. |
| Compartment and topology | UniProt places ENO1 in cytoplasm, nucleus, and sometimes cell membrane; it has no transmembrane segment (UniProt P06733: subcellular location and topology). Interpret a possible membrane rim alongside intracellular signal and controls rather than assuming that all membrane-associated color is off-target. |
| Isoforms and antibody coverage | UniProt lists alpha-enolase and MBP-1 isoforms (UniProt P06733: isoforms). The supplied records give no epitope or isoform coverage for the catalog antibody, so a change in nuclear versus cytoplasmic staining cannot be assigned to one isoform from this IHC image alone. |
| Antibody evidence | Three listed antibodies have Supported IHC status, whereas two have no IHC status in the supplied list (HPA antibodies: CAB018614, CAB069394, CAB080034; HPA068284, HPA068721). HPA also flags medium RNA–staining consistency and a splice or transcript discrepancy for tissue IHC (HPA tissue IHC: reliability). Keep those limits in mind when comparing sections. |
| IF/ICC Q&A: where should signal appear? | HPA describes enhanced plasma-membrane and cytosol localization in ICC-IF images; UniProt also permits nuclear localization (HPA subcellular ICC-IF: main location; UniProt P06733: subcellular location). Use the IF/ICC guide for that application; the ICC-IF localization summary does not supply a paraffin-IHC protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| No color in bronchial basal cells. | The expected high-staining cells may be absent, or the staining run may have failed (HPA tissue IHC: High in bronchial basal cells; general IHC practice). | Confirm cell identity on the counterstain, then inspect the concurrent positive control and detection steps; optimize retrieval as general paraffin-IHC practice. |
| Strong staining throughout cardiomyocytes. | This differs from the reported Low level, but Low does not mean absent (HPA tissue IHC: Low in cardiomyocytes). | Compare with a matched reference and no-primary control; review exposure or chromogen development and antibody dilution as general IHC practice. |
| Only a membrane rim is visible. | Membrane localization is biologically possible, although tissue IHC is described chiefly as cytoplasmic and nuclear (UniProt P06733: subcellular location; HPA tissue IHC: profile). | Check cell boundaries, intracellular staining, and controls before deciding whether the rim is specific (general IHC practice). |
| Color remains in the no-primary control. | The signal can arise from endogenous detection activity or nonspecific reagent deposition (general IHC practice). | Review the detection-system block and background controls, then repeat scoring on a clean run (general IHC practice). |
| Cytoplasm is obscured by diffuse haze. | Excess background can prevent compartment scoring (general IHC practice). | Check blocking, washes, antibody dilution, and chromogen development; score only clear cell-bound signal (general IHC practice). |
| Nuclear staining differs between sections. | Nuclear ENO1 is reported, but the supplied records do not identify which isoform an individual IHC antibody detects (HPA tissue IHC: profile; UniProt P06733: isoforms). | Compare matched cells and controls, and check documented antibody epitope coverage before assigning an isoform explanation (general IHC practice). |
Experiment evidence
IHC & IF images showing ENO1 staining
A01250-1 · IHCIHC analysis of ENO1 using anti-ENO1 antibody (A01250-1). ENO1 was detected in paraffin-embedded section of human liver cancer tissue. Heat
A01250-1 · IHCIHC analysis of ENO1 using anti-ENO1 antibody (A01250-1). ENO1 was detected in paraffin-embedded section of mouse testis tissue. Heat mediat
A01250-1 · IFIF analysis of ENO1 using anti-ENO1 antibody (A01250-1). ENO1 was detected in immunocytochemical section of A431 cells. Enzyme antigen retri
A01250-3 · IHCIHC analysis of ENO1 using anti-ENO1 antibody (A01250-3). ENO1 was detected in a paraffin-embedded section of mouse testis tissue. Heat medi
A01250-3 · IHCIHC analysis of ENO1 using anti-ENO1 antibody (A01250-3). ENO1 was detected in a paraffin-embedded section of rat testis tissue. Heat mediat
M01250 · IHCImmunohistochemical analysis of paraffin-embedded human colon, using ENO1 Antibody.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000074800-ENO1/tissue/cerebral+cortex#imid_18620876
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000074800-ENO1/tissue/colon#imid_18620794
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000074800-ENO1/tissue/liver#imid_18620795
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000074800-ENO1/tissue/pancreas#imid_18620746
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody CAB018614; green = ENO1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody CAB018614; green = ENO1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ENO1 IHC & IF
🧪Run bronchus first and confirm staining in basal cells (HPA: High in bronchus basal cells). HPA detects ENO1 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and expect any unstained cells on the positive slide to show counterstain without DAB, without treating them as a validated ENO1-negative population (HPA: no negative rows).
Positive control tissue: Bronchus (Basal cells, HPA High)
Negative control tissue: None in HPA: ENO1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ENO1 in A-549, MCF-7, U2OS, HeLa, A-431, PC-3, with annotated localisation: Plasma membrane (enhanced), Cytosol (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide; a concentration-matched rabbit isotype control with clonality matched to the primary antibody if known; and an ENO1 knockout sample or validated peptide-block control (selected-SKU caption: rabbit primary antibody). Check endogenous peroxidase and biotin background in bronchus with the selected biotin–streptavidin/DAB detection scheme (selected-SKU caption: biotinylated secondary, SABC and DAB).
⚠️Feasibility: The selected-SKU paraffin-section caption reports EDTA retrieval at pH 8.0, but reports no fixative; no target-specific fixation window or fixation effect is supplied (selected-SKU tissue-IHC caption). Frozen sections cannot be judged easier from these data; ICC-IF images support IF feasibility in the listed cell lines and show plasma membrane and cytosol localization (HPA: subcellular summary). For bronchus IHC, assess background from the biotin–streptavidin/DAB detection scheme with the controls above (selected-SKU caption: SABC and DAB).
HPA tissue IHC evidence for ENO1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data. Caution, Splice and/or transcript discrepancy exists.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bronchus | Basal cells | High | Protein (IHC) | HPA → |
| Fallopian tube | Non-ciliated cells | High | Protein (IHC) | HPA → |
| Lung | Alveolar cells type I | High | Protein (IHC) | HPA → |
| Adipose tissue | Adipocytes | Medium | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: ENO1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced ENO1 IHC Tips
Troubleshoot ENO1 staining in paraffin sections by checking retrieval, compartment patterns and controls before comparing staining across samples.
How should I retrieve ENO1 antigen when paraffin sections stain weakly?
Use heat-mediated antigen retrieval in EDTA at pH 8.0 before chromogenic staining of paraffin sections (datasheet A01250-1). The documented assay used 1 μg/ml antibody overnight at 4°C; match those conditions before attributing weak staining to retrieval (A01250-1 caption). Check section adhesion, heating consistency, buffer preparation and a positive control, then vary one retrieval parameter at a time if signal remains weak (standard IHC practice). Assess cytoplasmic and nuclear signal because both occur in tissue, while membrane-associated ENO1 can also occur (HPA tissue IHC; UniProt P06733 localisation). Record each adjustment alongside its control result so changes in signal can be assigned to the adjusted step (standard IHC practice).
Can fixation explain weak or uneven ENO1 staining in paraffin sections?
Target-specific fixation sensitivity is unknown: the selected ENO1 tissue caption describes paraffin embedding but does not state a fixative (A01250-1 caption). Document the actual fixative and fixation duration for every specimen before comparing staining, because these preanalytical conditions can affect antigen preservation and morphology (standard IHC practice). If signal varies across a batch, compare sections processed and stained together, then inspect tissue preservation and section thickness before changing antibody concentration (standard IHC practice). Use the documented EDTA pH 8.0 retrieval and 1 μg/ml antibody conditions as starting points, while treating any fixation adjustment as an experiment requiring controls (A01250-1 caption; standard IHC practice).
Which cellular compartments should count as plausible ENO1 staining?
Score cytoplasmic and nuclear staining separately, because tissue IHC reports ubiquitous expression in both compartments (HPA tissue IHC). Membrane-associated signal can also be plausible: ENO1 can translocate to the plasma membrane despite having no transmembrane segment (UniProt P06733 localisation; UniProt P06733 topology). On each slide, record the fraction of cells stained and the dominant compartment within the same annotated tissue region (standard IHC practice). The documented paraffin assay used DAB detection, so compare compartment patterns against a matched negative control and hematoxylin counterstain rather than relying on brown color alone (A01250-1 caption; standard IHC practice). Unexpected compartment patterns warrant repeat staining and review of tissue morphology (standard IHC practice).
Can this antibody distinguish alpha-enolase from the MBP-1 isoform?
Do not assign an isoform from chromogenic staining alone: ENO1 has alpha-enolase and MBP-1 isoforms, and the supplied antibody caption does not identify its epitope (UniProt P06733 isoforms; A01250-1 caption). Ask whether the immunogen and mapped binding site are shared before interpreting either nuclear or cytoplasmic signal as isoform-specific (standard IHC practice). ENO1 also has annotated modifications, including phosphoserine at residue 27 and phosphotyrosine at residue 44, but their effects on this antibody are unreported (UniProt P06733 modified residues; A01250-1 caption). Use an independently validated isoform-specific assay if the biological question requires that distinction, and report this IHC result as ENO1 staining until specificity is established (standard IHC practice).
How should I check ENO1 localisation in a multiplex IF experiment?
Pair ENO1 with a marker for the expected cell type and verify that each signal can be assigned to the same cell (standard IF practice). Choose fluorophores after checking unstained tissue autofluorescence, reserving a spectrally distinct channel for ENO1 where background is lowest (standard IF practice). Include single-stain controls when setting acquisition and assessing channel bleed-through, and keep exposure settings consistent across compared samples (standard IF practice). ENO1 lacks a transmembrane segment but can appear at the plasma membrane as well as in the cytosol; choose permeabilisation according to whether the antibody must access an intracellular epitope, and compare permeabilised with non-permeabilised controls if surface staining matters (UniProt P06733 topology and localisation; standard IF practice). The selected antibody caption establishes paraffin-section IHC conditions, not IF performance (A01250-1 caption).
How can I separate ENO1 signal from chromogenic background?
Start with a negative control that omits the primary antibody, then examine whether diffuse DAB deposition persists in the same tissue regions (standard IHC practice). Apply a peroxidase block as a general chromogenic IHC step and check for endogenous biotin interference when using the documented biotinylated secondary and streptavidin-biotin complex (A01250-1 caption; standard IHC practice). The documented section was blocked with 10% goat serum, incubated with 1 μg/ml primary antibody, and developed with DAB (A01250-1 caption). If background remains high, assess blocking, washes and detection controls one step at a time while preserving a comparable positive control (standard IHC practice). Broad cytoplasmic staining alone cannot establish background because ENO1 expression is widespread (HPA tissue IHC).
What should I measure when comparing ENO1 IHC across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define tissue regions and cell populations before scoring, then measure the percentage of positive cells and staining intensity within each region (standard IHC practice). An H-score combines intensity categories with their positive-cell percentages; report the scoring thresholds and assess cytoplasmic and nuclear signal separately (standard IHC practice; HPA tissue IHC). For spatial questions, count ENO1-positive cells per mm² of viable annotated tissue, rather than per whole section when tissue area varies (standard IHC practice). Normalise comparisons to the same cell population, viable tissue area and staining batch, and include a matched reference section to monitor run variation (standard IHC practice). Report membrane-associated staining separately when it is the outcome of interest (UniProt P06733 localisation; standard IHC practice).
When is an unusual ENO1 staining pattern convincing rather than artefactual?
A plausible result follows cellular boundaries and shows interpretable cytoplasmic, nuclear or membrane-associated staining in preserved cells (HPA tissue IHC; UniProt P06733 localisation; standard IHC practice). Check cell identity against morphology: tissue IHC reports high signal in bronchial basal cells and lung alveolar type I cells, while muscle cell groups in the supplied profile are low (HPA tissue IHC). Treat staining concentrated at section edges or in necrotic areas as suspect until it repeats in intact regions and independent sections (standard IHC practice). Exclude endogenous enzyme signal with a primary-omission control and appropriate peroxidase blocking before calling focal DAB deposition ENO1-positive (standard IHC practice). HPA rates tissue staining as Supported but notes medium RNA agreement and transcript discrepancy, so avoid inferring isoform identity from intensity alone (HPA tissue IHC).
Boster reagents
Best ENO1 / Alpha-enolase IHC Antibodies
The catalog shows paraffin-section IHC in human, mouse and rat tissues (A01250-1 and A01250-3 IHC captions), plus IF in human A431 cells (A01250-1 IF caption).
Real IHC data
Anti-ENO1 Antibody ®
Cat # A01250-1
Real IHC data
Anti-ENO1 Antibody ®
Cat # A01250-3
Real IHC data
Anti-ENO1/Alpha Enolase Rabbit Monoclonal Antibody
Cat # M01250
A01250-1 shows paraffin-section IHC in human liver cancer and mouse and rat testis, plus IF in A431 cells (A01250-1 image captions); A01250-3 shows paraffin-section IHC in mouse and rat testis and human cerebellum (A01250-3 IHC captions). M01250 lists IF/ICC among its applications and has a paraffin-section human colon IHC caption, although IHC is absent from its application list (M01250 catalog applications and IHC caption).
Which to pick: Choose A01250-1 for tissue IHC when documented human, mouse and rat examples are useful; A01250-3 also has paraffin-section IHC examples in those species (A01250-1 and A01250-3 IHC captions). For IF/ICC, A01250-1 has a direct A431 IF example, while monoclonal M01250 lists IF/ICC without an IF image in this payload (A01250-1 IF caption; M01250 catalog applications and image captions). A01250-1 has the broadest listed reactivity, including monkey, though its IHC captions cover only human, mouse and rat; neither tissue antibody’s IHC captions report the fixative (A01250-1 catalog reactivity and IHC captions; A01250-3 IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P06733 (ENOA_HUMAN, Alpha-enolase).
- Human Protein Atlas. ENO1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. ENO1 subcellular location (ICC-IF): Mainly localized to the plasma membrane and cytosol..
- Human Protein Atlas. ENO1 antibody validation summary (5 antibodies).
- Immunohistochemical analysis of Enolase-1 sublocalization in benign and malignant breast tumors: potential implications for tumor progression and prognosis. Frontiers in oncology 2025 — PMC12571633.
- High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia. Cancers 2024 — PMC10931177.
- Impact of Tissue Enolase 1 Protein Overexpression in Esophageal Cancer Progression. International journal of medical sciences 2021 — PMC7893569.
- Arsenic, cadmium and neuron specific enolase (ENO2, γ-enolase) expression in breast cancer. Cancer cell international 2011 — PMC3233504.
- PubMed PMID:3529090 — UniProt-cited evidence.
- PubMed PMID:2373081 — UniProt-cited evidence.
- PubMed PMID:2005901 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ENO1 (Alpha-enolase). Expected localisation Cytoplasmic and nuclear staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A01250-1). Validated IHC antibody: A01250-1 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bronchus (Basal cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human liver cancer tissue; fixative not specified (datasheet A01250-1); 2. Fixation: Image fixative and duration unreported (datasheet A01250-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A01250-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A01250-1); 8. Primary antibody: Rabbit anti-ENO1, 0.5-1μg/ml (datasheet A01250-1); 9. Primary incubation: Overnight at 4 °C (datasheet A01250-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific). Selected-image fixative and duration unreported (datasheet A01250-1); verify before use.; Caveat: Splice or transcript discrepancies may complicate interpretation (HPA tissue IHC); Isoform / epitope: 2 isoforms: alpha-enolase and MBP-1; check epitope coverage (UniProt); Regulation: Alpha/alpha occurs in most adult tissues (UniProt). Evidence: UniProt P06733, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the plasma membrane and cytosol., Datasheet A01250-1, PMC12571633, PMC10931177. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ENO1/immunohistochemistry-ihc-guide.